Breaking News

Today
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Syndicate
Vigil Neuroscience announces $75M private placement finanicng » 07:13
08/12/22
08/12
07:13
08/12/22
07:13
VIGL

Vigil Neuroscience

$7.29 /

+0.13 (+1.82%)

Vigil Neuroscience…

Vigil Neuroscience announced that it has entered into a securities purchase agreement with certain existing and new accredited investors to issue and sell an aggregate of 7,293,084 shares of its common stock at a price of $7.30 per share and pre-funded warrants to purchase up to an aggregate of 2,980,889 shares of common stock at a purchase price of $7.2999 per pre-funded warrant, through a private investment in public equity, or PIPE, financing. The PIPE was led by existing investor, Deep Track Capital LP, and included participation from new investors including BVF Partners and an investment fund affiliated with Deerfield Management Company, L.P., as well as existing investors including Invus and DAFNA Capital Management LLC.

ShowHide Related Items >><<
VIGL Vigil Neuroscience
$7.29 /

+0.13 (+1.82%)

VIGL Vigil Neuroscience
$7.29 /

+0.13 (+1.82%)

02/01/22 Morgan Stanley
Morgan Stanley starts Vigil at Equal Weight ahead of 2023 derisking catalysts
02/01/22 Stifel
Stifel starts Vigil Neuroscience at Buy with $24 price target
02/01/22 Guggenheim
Vigil Neuroscience initiated with a Buy at Guggenheim
02/01/22 Stifel
Vigil Neuroscience initiated with a Buy at Stifel
VIGL Vigil Neuroscience
$7.29 /

+0.13 (+1.82%)

  • 07
    Jan
VIGL Vigil Neuroscience
$7.29 /

+0.13 (+1.82%)

Monday
Earnings
Vigil Neuroscience reports Q2 EPS (60c) vs ($7.48) last year » 07:04
08/08/22
08/08
07:04
08/08/22
07:04
VIGL

Vigil Neuroscience

$7.75 /

+0.695 (+9.86%)

Cash and cash equivalents…

Cash and cash equivalents were $148.9 million as of June 30, 2022. The Company expects its cash and cash equivalents to fund its operational plans through the end of the second quarter of 2024. "We continue to make significant progress in our VGL101 program, including the initiation of our Phase 1 study in healthy volunteers in Australia. In addition, the FDA recently granted VGL101 orphan drug designation for the treatment of ALSP supporting the significant unmet need of ALSP patients. We remain on track to report VGL101 Phase 1 topline data and to initiate a Phase 2 proof-of-concept trial for VGL101 in ALSP in the fourth quarter of 2022," said Ivana Magovcevic-Liebisch, Ph.D., J.D., President and Chief Executive Officer of Vigil. "We are also excited about the progress we've made with our first-in-class small molecule TREM2 agonist program. We continue to advance our IND-enabling work and plan to move our small molecule program into the clinic next year." Dr. Magovcevic-Liebisch continued, "As part of the continuous evaluation of our programs we have elected to prioritize VGL101 in ALSP and our small molecule TREM2 agonist programs, which will extend our cash runway and also better position us to continue advancing these potentially transformative treatments for patients with both rare and common neurodegenerative diseases."

ShowHide Related Items >><<
VIGL Vigil Neuroscience
$7.75 /

+0.695 (+9.86%)

VIGL Vigil Neuroscience
$7.75 /

+0.695 (+9.86%)

02/01/22 Morgan Stanley
Morgan Stanley starts Vigil at Equal Weight ahead of 2023 derisking catalysts
02/01/22 Stifel
Stifel starts Vigil Neuroscience at Buy with $24 price target
02/01/22 Guggenheim
Vigil Neuroscience initiated with a Buy at Guggenheim
02/01/22 Stifel
Vigil Neuroscience initiated with a Buy at Stifel
VIGL Vigil Neuroscience
$7.75 /

+0.695 (+9.86%)

  • 07
    Jan
VIGL Vigil Neuroscience
$7.75 /

+0.695 (+9.86%)

Over a week ago
Hot Stocks
Vigil Neuroscience presents preclinical data on VGL101 » 07:15
08/01/22
08/01
07:15
08/01/22
07:15
VIGL

Vigil Neuroscience

$6.83 /

+0.02 (+0.29%)

Vigil Neuroscience…

Vigil Neuroscience presented two posters at the Alzheimer's Association International Conference, AAIC, in San Diego. The first poster titled "VGL101 Rescues CSF1R Dysfunction in Human Microglia and Macrophages: Evaluation of In Vitro TREM2 Agonism in Models of a CSF1R-dependent Leukodystrophy" demonstrates that TREM2 agonism by VGL101 was able to compensate for CSF1R dysfunction in in vitro ALSP models utilizing healthy, human monocyte derived macrophages and induced pluripotent stem cell derived human microglia, providing a rational basis for developing VGL101 as a potential therapeutic for ALSP. Key highlights from the presentation include: CSF1R inhibition by PLX5622 or CSF1R ligands withdrawal resulted in decreased viability, increased caspase 3/7 activation, and an altered morphology. VGL101 administration induced phosphorylation of SYK in both hMDM and iMGL models, demonstrating agonism of the TREM2 receptor. VGL101 rescued CSF1R inhibition-induced morphology and cell death in both hMDM and iMGL. Increases in soluble CSF1R and decreases in soluble TREM2 upon VGL101 administration in iMGLs may inform target engagement studies. In a separate poster titled "Phenotypic Features of Adult-Onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia: Presenting Symptoms and Clinical Course," Vigil conducted a systematic literature review of published case studies on the clinical and genetic features of ALSP to better understand the phenotypic characteristics of ALSP, with data extracted from a cohort of 292 patients, representing the largest case series to date of ALSP. The findings of this study supported and expanded the previous, smaller case reports on the phenotypic characteristics of ALSP. Key highlights from the presentation include: The mean age of onset of symptoms was 43.2, survival time was 6.1, age of death was 52.2 and the number of deaths was 118. Family history was considerably more frequent than absence of family history, supporting that genetic testing for CSF1R mutations should be used as a key marker for early and accurate diagnosis of ALSP. The most common initial symptoms were cognitive impairment, behavioral and psychiatric dysfunction, extrapyramidal and pyramidal motor abnormalities and speech difficulty. The clinical symptoms at disease onset reinforced ALSP phenotypic heterogeneity, a significant contributor to frequent misdiagnosis of ALSP as Alzheimer's disease or frontotemporal dementia.

ShowHide Related Items >><<
VIGL Vigil Neuroscience
$6.83 /

+0.02 (+0.29%)

VIGL Vigil Neuroscience
$6.83 /

+0.02 (+0.29%)

02/01/22 Morgan Stanley
Morgan Stanley starts Vigil at Equal Weight ahead of 2023 derisking catalysts
02/01/22 Stifel
Stifel starts Vigil Neuroscience at Buy with $24 price target
02/01/22 Guggenheim
Vigil Neuroscience initiated with a Buy at Guggenheim
02/01/22 Stifel
Vigil Neuroscience initiated with a Buy at Stifel
VIGL Vigil Neuroscience
$6.83 /

+0.02 (+0.29%)

  • 07
    Jan
VIGL Vigil Neuroscience
$6.83 /

+0.02 (+0.29%)

Hot Stocks
Vigil Neuroscience appoints Suzanne Bruhn to board of directors » 07:19
07/28/22
07/28
07:19
07/28/22
07:19
VIGL

Vigil Neuroscience

$6.99 /

+0.25 (+3.71%)

Vigil Neuroscience…

Vigil Neuroscience announced the appointment of Suzanne Bruhn, Ph.D. to its Board of Directors. She is currently President and CEO of Tiaki Therapeutics.

ShowHide Related Items >><<
VIGL Vigil Neuroscience
$6.99 /

+0.25 (+3.71%)

VIGL Vigil Neuroscience
$6.99 /

+0.25 (+3.71%)

02/01/22 Morgan Stanley
Morgan Stanley starts Vigil at Equal Weight ahead of 2023 derisking catalysts
02/01/22 Stifel
Stifel starts Vigil Neuroscience at Buy with $24 price target
02/01/22 Guggenheim
Vigil Neuroscience initiated with a Buy at Guggenheim
02/01/22 Stifel
Vigil Neuroscience initiated with a Buy at Stifel
VIGL Vigil Neuroscience
$6.99 /

+0.25 (+3.71%)

  • 07
    Jan
VIGL Vigil Neuroscience
$6.99 /

+0.25 (+3.71%)

Hot Stocks
Vigil Neuroscience granted orphan status for leukoencephalopathy treatment » 12:38
07/27/22
07/27
12:38
07/27/22
12:38
VIGL

Vigil Neuroscience

$6.96 /

+0.22 (+3.26%)

The FDA granted Vigil…

The FDA granted Vigil Neuroscience orphan status for its human monoclonal IgG1 TREM2 agonist antibody for the treatment of adult-onset leukoencephalopathy with axonal spheroids and pigmented glia. Reference Link

ShowHide Related Items >><<
VIGL Vigil Neuroscience
$6.96 /

+0.22 (+3.26%)

VIGL Vigil Neuroscience
$6.96 /

+0.22 (+3.26%)

02/01/22 Morgan Stanley
Morgan Stanley starts Vigil at Equal Weight ahead of 2023 derisking catalysts
02/01/22 Stifel
Stifel starts Vigil Neuroscience at Buy with $24 price target
02/01/22 Guggenheim
Vigil Neuroscience initiated with a Buy at Guggenheim
02/01/22 Stifel
Vigil Neuroscience initiated with a Buy at Stifel
VIGL Vigil Neuroscience
$6.96 /

+0.22 (+3.26%)

  • 07
    Jan
VIGL Vigil Neuroscience
$6.96 /

+0.22 (+3.26%)

Over a month ago
Conference/Events
Vigil Neuroscience management to meet virtually with Stifel » 04:55
06/27/22
06/27
04:55
06/27/22
04:55
VIGL

Vigil Neuroscience

$2.87 /

+0.47 (+19.58%)

Virtual Meeting to be…

Virtual Meeting to be held on June 27 hosted by Stifel.

ShowHide Related Items >><<
VIGL Vigil Neuroscience
$2.87 /

+0.47 (+19.58%)

VIGL Vigil Neuroscience
$2.87 /

+0.47 (+19.58%)

02/01/22 Morgan Stanley
Morgan Stanley starts Vigil at Equal Weight ahead of 2023 derisking catalysts
02/01/22 Stifel
Stifel starts Vigil Neuroscience at Buy with $24 price target
02/01/22 Guggenheim
Vigil Neuroscience initiated with a Buy at Guggenheim
02/01/22 Stifel
Vigil Neuroscience initiated with a Buy at Stifel
VIGL Vigil Neuroscience
$2.87 /

+0.47 (+19.58%)

  • 07
    Jan
VIGL Vigil Neuroscience
$2.87 /

+0.47 (+19.58%)

Conference/Events
Vigil Neuroscience management to meet virtually with Stifel » 17:12
06/21/22
06/21
17:12
06/21/22
17:12
VIGL

Vigil Neuroscience

$2.45 /

-0.235 (-8.75%)

Virtual Meeting to be…

Virtual Meeting to be held on June 27 hosted by Stifel.

ShowHide Related Items >><<
VIGL Vigil Neuroscience
$2.45 /

-0.235 (-8.75%)

VIGL Vigil Neuroscience
$2.45 /

-0.235 (-8.75%)

02/01/22 Morgan Stanley
Morgan Stanley starts Vigil at Equal Weight ahead of 2023 derisking catalysts
02/01/22 Stifel
Stifel starts Vigil Neuroscience at Buy with $24 price target
02/01/22 Guggenheim
Vigil Neuroscience initiated with a Buy at Guggenheim
02/01/22 Stifel
Vigil Neuroscience initiated with a Buy at Stifel
VIGL Vigil Neuroscience
$2.45 /

-0.235 (-8.75%)

  • 07
    Jan
VIGL Vigil Neuroscience
$2.45 /

-0.235 (-8.75%)

Hot Stocks
Vigil gets HREC approval to begin study of VGL101 in healthy volunteers » 07:25
06/07/22
06/07
07:25
06/07/22
07:25
VIGL

Vigil Neuroscience

$3.00 /

-0.34 (-10.18%)

Vigil Neuroscience…

Vigil Neuroscience announced it has received approval from the Australian Human Research Ethics Committee HREC to initiate a Phase 1 study of VGL101 in healthy volunteers without dosing restrictions. Under the approved protocol, the Company will evaluate VGL101 at doses above 20 mg/kg allowing for immediate exploration of higher doses with a focus on maintaining optionality for future indications. In regard to the VGL101 Phase 1 trial in the U.S., the Food and Drug Administration has suggested that Vigil may wish to consider the feasibility of administration of a 30 mg/kg dose. This progress with the FDA was made in response to Vigil's most recent submission of data from a 6-month GLP toxicology study in nonhuman primates (in which there were no observed adverse findings) and Phase 1 single ascending dose clinical data that includes patients dosed at 20 mg/kg. The partial clinical hold that limits dosing above 20 mg/kg remains in effect while Vigil continues to work with the FDA to lift the partial clinical hold. Importantly, Vigil remains on track to report VGL101 Phase 1 topline data and initiate the Phase 2 proof-of-concept trial in adult-onset leukoencephalopathy with axonal spheroids and pigmented glia patients in the fourth quarter of 2022. "We are encouraged by the favorable safety, tolerability and pharmacokinetic profile of VGL101 based on data from our ongoing Phase 1 healthy volunteer trial to date. Although we believe that 20 mg/kg is a clinically relevant dose to assess the therapeutic effects of VGL101 in ALSP, we look forward to continuing to explore a wider dose range and cerebral spinal fluid target engagement biomarkers in healthy volunteers. We believe that, collectively, the data from the Phase 1 trial will contribute to declaration of biological target engagement and help further refine dose selection for the Phase 2 proof-of-concept trial in ALSP," said Spyros Papapetropoulos, M.D., Ph.D., Chief Medical Officer of Vigil.

ShowHide Related Items >><<
VIGL Vigil Neuroscience
$3.00 /

-0.34 (-10.18%)

VIGL Vigil Neuroscience
$3.00 /

-0.34 (-10.18%)

02/01/22 Morgan Stanley
Morgan Stanley starts Vigil at Equal Weight ahead of 2023 derisking catalysts
02/01/22 Stifel
Stifel starts Vigil Neuroscience at Buy with $24 price target
02/01/22 Guggenheim
Vigil Neuroscience initiated with a Buy at Guggenheim
02/01/22 Stifel
Vigil Neuroscience initiated with a Buy at Stifel
VIGL Vigil Neuroscience
$3.00 /

-0.34 (-10.18%)

  • 07
    Jan
VIGL Vigil Neuroscience
$3.00 /

-0.34 (-10.18%)

Over a quarter ago
Hot Stocks
Vigil Neuroscience sees cash, equivalents funding operational plans into 2024  07:25
05/12/22
05/12
07:25
05/12/22
07:25
VIGL

Vigil Neuroscience

$2.21 /

-0.73 (-24.83%)

 
ShowHide Related Items >><<
VIGL Vigil Neuroscience
$2.21 /

-0.73 (-24.83%)

VIGL Vigil Neuroscience
$2.21 /

-0.73 (-24.83%)

02/01/22 Morgan Stanley
Morgan Stanley starts Vigil at Equal Weight ahead of 2023 derisking catalysts
02/01/22 Stifel
Stifel starts Vigil Neuroscience at Buy with $24 price target
02/01/22 Guggenheim
Vigil Neuroscience initiated with a Buy at Guggenheim
02/01/22 Stifel
Vigil Neuroscience initiated with a Buy at Stifel
VIGL Vigil Neuroscience
$2.21 /

-0.73 (-24.83%)

  • 07
    Jan
VIGL Vigil Neuroscience
$2.21 /

-0.73 (-24.83%)

Hot Stocks
Vigil Neuroscience on track to report VGL101 Phase 1 data in 2H » 07:25
05/12/22
05/12
07:25
05/12/22
07:25
VIGL

Vigil Neuroscience

$2.21 /

-0.73 (-24.83%)

The Company is on track…

The Company is on track to report VGL101 Phase 1 topline data and initiate a Phase 2 proof-of-concept trial in ALSP patients in the second half of 2022: Vigil completed dosing of the 20 mg/kg single ascending dose cohort without any safety signals and is currently dosing the 20 mg/kg multiple ascending dose cohort in its Phase 1 trial of VGL101, an investigational, fully human monoclonal antibody TREM2 agonist, in healthy volunteers. Vigil continues to engage with the Food and Drug Administration regarding the partial clinical hold at doses above 20 mg/kg. Accordingly, Vigil submitted data to the FDA from a 6-month GLP toxicology study in nonhuman primates in which there were no observed adverse findings and Phase 1 SAD clinical data. Vigil remains on track to initiate the Phase 2 proof-of-concept trial in the second half of 2022 and believes that 20 mg/kg is a clinically-relevant dose in ALSP. The Company continues to expect to initiate a Phase 1b trial of VGL101 for Alzheimer's disease (AD) in the second half of 2022: Vigil plans to initiate a Phase 1b biomarker-based clinical trial with VGL101 in genetically defined populations of AD patients with or without the relevant TREM2 variants.

ShowHide Related Items >><<
VIGL Vigil Neuroscience
$2.21 /

-0.73 (-24.83%)

VIGL Vigil Neuroscience
$2.21 /

-0.73 (-24.83%)

02/01/22 Morgan Stanley
Morgan Stanley starts Vigil at Equal Weight ahead of 2023 derisking catalysts
02/01/22 Stifel
Stifel starts Vigil Neuroscience at Buy with $24 price target
02/01/22 Guggenheim
Vigil Neuroscience initiated with a Buy at Guggenheim
02/01/22 Stifel
Vigil Neuroscience initiated with a Buy at Stifel
VIGL Vigil Neuroscience
$2.21 /

-0.73 (-24.83%)

  • 07
    Jan
VIGL Vigil Neuroscience
$2.21 /

-0.73 (-24.83%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.